Virtus LifeSci Biotech Clinical Trials ETF (BBC)
|Day's Range||20.63 - 20.66|
|Inception Date||Dec 16, 2014|
About BBCFund Home Page
The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is issued by Virtus Investment Partners.
Top 10 Holdings21.04% of assets
|Bny Mellon Cash Reserve Usd||n/a||2.98%|
|Revolution Medicines, Inc.||RVMD||2.64%|
|CymaBay Therapeutics, Inc.||CBAY||2.52%|
|Structure Therapeutics Inc.||GPCR||2.24%|
|Crinetics Pharmaceuticals, Inc.||CRNX||1.77%|
|Mirati Therapeutics, Inc.||MRTX||1.67%|
|Dec 20, 2017||$0.29724||Dec 27, 2017|
|Dec 21, 2015||$0.14733||Dec 29, 2015|
In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way wit...
Biotechnology sector-related exchange traded funds were in a bright spot on Friday after Bristol Myers Squibb Co. (NYSE: BMY) said it will acquire drug developers Turning Point Therapeutics (NasdaqGS:...
Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader...
Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALP...
While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se...
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...
Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.
Biotechnology ETFs, including the ALPS Medical Breakthroughs ETF (SBIO), are on torrid paces in the second quarter. Yes, some of that bullishness is attributable to the industry’s efforts to vanquish ...
Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be
Bloomberg's Eric Balchunas and Scarlet Fu break down the Virtus LifeSci Biotech Clinical Trials ETF (ticker: BBC) with Paul Yook, CIO of LifeSci Venture Partners.
Despite concerns of a spreading coronavirus out of China, biotechnology stocks and sector-related ETFs are not enjoying the usual bump on hopes of developing new treatments to counter the contagion. A...